Page last updated: 2024-09-05

lenalidomide and warfarin

lenalidomide has been researched along with warfarin in 7 studies

Compound Research Comparison

Studies (lenalidomide)	Trials (lenalidomide)	Recent Studies (post-2010) (lenalidomide)	Studies (warfarin)	Trials (warfarin)	Recent Studies (post-2010) (warfarin)
3,532	725	2,850	36,573	2,143	14,728

Protein Interaction Comparison

Protein	Taxonomy	lenalidomide (IC50)	warfarin (IC50)
Vitamin K epoxide reductase complex subunit 1	Homo sapiens (human)		0.0088

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (14.29)	29.6817
2010's	6 (85.71)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Anderson, KC; Attal, M; Barlogie, B; Belch, A; Bladé, J; Boccadoro, M; Bringhen, S; Cavo, M; Dimopoulos, MA; Durie, BG; Harousseau, J; Hussein, MA; Joshua, D; Knop, S; Kyle, R; Lonial, S; Ludwig, H; Morgan, GJ; Niesvizky, R; Orlowski, RZ; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Shimizu, K; Sonneveld, P; Vesole, D; von Lilienfeld-Toal, M; Waage, A; Weber, D; Westin, J; Zangari, M; Zonder, JA	1
Gajra, A; Singh, A	1
Brioli, A; Cavo, M; Pantani, L; Tacchetti, P; Zamagni, E; Zannetti, B	1
Alexander, M; Kirsa, S; Lingaratnam, S; Mellor, JD; Teoh, KC	1
Chen, N; Knight, R; Palmisano, M; Weiss, D; Zhou, S	1
Leebeek, FW	1

Reviews

4 review(s) available for lenalidomide and warfarin

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008, Volume: 22, Issue:2 Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Lenalidomide; Multiple Myeloma; Premedication; Risk Assessment; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism; Warfarin	2008
Thromboembolism with immunomodulatory agents in the treatment of multiple myeloma. Cardiovascular & hematological agents in medicinal chemistry, 2011, Volume: 9, Issue:1 Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide; Thromboembolism; Warfarin	2011
Update of thrombosis in multiple myeloma. Thrombosis research, 2016, Volume: 140 Suppl 1 Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Thrombosis; Warfarin	2016

Trials

1 trial(s) available for lenalidomide and warfarin

Article	Year
Evaluation of pharmacokinetic and pharmacodynamic interactions when lenalidomide is co-administered with warfarin in a randomized clinical trial setting. Clinical drug investigation, 2015, Volume: 35, Issue:7 Topics: Adult; Anticoagulants; Cross-Over Studies; Double-Blind Method; Drug Interactions; Female; Humans; Immunologic Factors; International Normalized Ratio; Lenalidomide; Male; Middle Aged; Prothrombin Time; Thalidomide; Warfarin; Young Adult	2015

Article

Year

Evaluation of pharmacokinetic and pharmacodynamic interactions when lenalidomide is co-administered with warfarin in a randomized clinical trial setting.

Clinical drug investigation, 2015, Volume: 35, Issue:7

Topics: Adult; Anticoagulants; Cross-Over Studies; Double-Blind Method; Drug Interactions; Female; Humans; Immunologic Factors; International Normalized Ratio; Lenalidomide; Male; Middle Aged; Prothrombin Time; Thalidomide; Warfarin; Young Adult

2015

Other Studies

2 other study(ies) available for lenalidomide and warfarin

Article	Year
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. Seminars in thrombosis and hemostasis, 2011, Volume: 37, Issue:3 Topics: Activated Protein C Resistance; Aged; Anticoagulants; Aspirin; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunologic Factors; International Normalized Ratio; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism; Warfarin	2011
Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital. Asia-Pacific journal of clinical oncology, 2013, Volume: 9, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anticoagulants; Aspirin; Cancer Care Facilities; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Practice Patterns, Physicians'; Prognosis; Retrospective Studies; Specialization; Thalidomide; Thrombosis; Warfarin	2013

Article

Year

Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.

Seminars in thrombosis and hemostasis, 2011, Volume: 37, Issue:3

Topics: Activated Protein C Resistance; Aged; Anticoagulants; Aspirin; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunologic Factors; International Normalized Ratio; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism; Warfarin

2011

Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital.

Asia-Pacific journal of clinical oncology, 2013, Volume: 9, Issue:2

Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anticoagulants; Aspirin; Cancer Care Facilities; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Practice Patterns, Physicians'; Prognosis; Retrospective Studies; Specialization; Thalidomide; Thrombosis; Warfarin

2013